Protagonist Therapeutics, Inc

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· 2025 · 2024 · 2025 · 2024
License and collaboration revenue	$4,712	$4,675	$38,579	$263,795
Operating expenses:
Research and development	40,003	35,970	112,932	103,224
General and administrative	11,130	10,158	33,419	34,508
Total operating expenses	51,133	46,128	146,351	137,732
(Loss) income from operations	(46,421)	(41,453)	(107,772)	126,063
Interest income	7,049	7,682	22,028	19,462
Other income, net	33	141	151	219
(Loss) income before income tax benefit (expense)	(39,339)	(33,630)	(85,593)	145,744
Income tax benefit (expense)	—	420	(172)	(2,230)
Net (loss) income	$(39,339)	$(33,210)	$(85,765)	$143,514
Net (loss) income per share, basic	$(0.62)	$(0.54)	$(1.35)	$2.34
Net (loss) income per share, diluted	$(0.62)	$(0.54)	$(1.35)	$2.22
Weighted-average shares used to compute net (loss) income per share, basic	63,772,332	61,767,934	63,418,522	61,311,310
Weighted-average shares used to compute net (loss) income per share, diluted	63,772,332	61,767,934	63,418,522	64,611,941

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.